Armata Pharmaceuticals

ARMP

Market cap $123M

LOS ANGELES , Oct. 14, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced it will be presenting late-breaking Phase 2a clinical data on its Staphylococcus aureus bacteriophage cocktail, AP-SA02, at IDWeek 2025 ™ , which is being held October 19-22, 2025, in Atlanta, GA. Details of the oral presentation are as follows: Presentation Title:          A Phase 2a Randomized, Double-Blind, Controlled Trial of the Efficacy and Safety of an Intravenous (IV) Bacteriophage Cocktail (AP-SA02) vs.

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Describes the structure of phage Pa223, which is included in Armata's multi-phage anti-Pseudomonas clinical candidate, AP-PA02 LOS ANGELES , Sept. 8, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced a paper in the Journal of Molecular Biology (JMB).

LOS ANGELES , Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D.

Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Here is how Armata Pharmaceuticals, Inc. (ARMP) and Avadel (AVDL) have performed compared to their sector so far this year.

Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to a loss of $0.65 per share a year ago.

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS ANGELES , Aug. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced financial results for its second quarter ended June 30, 2025, and provided a corporate update. Second Quarter 2025 and Recent Developments: On August 11, 2025, entered into a secured credit agreement with Innoviva Strategic Opportunities LLC, a wholly owned subsidiary of Innoviva, Inc., Armata's largest shareholder, for a loan of $15.0 million that will mature on January 11, 2029 Proceeds from the new financing transaction will be used to continue to advance development of Armata's lead Staphylococcus aureus ("S.

Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.